WILLANGIO: Impact of Von Willebrand Factor and Its Multimers on Angiogenesis
Study Details
Study Description
Brief Summary
The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| patients with von Willebrand disease
|
Other: no intervention
no intervention
|
| case control
|
Other: no intervention
no intervention
|
Outcome Measures
Primary Outcome Measures
- To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest [1 year]
Compare the distribution of multimers assays between different groups of patients and the control group
- To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest [1 year]
Compare the distribution of protein assays between different groups of patients and the control group
Secondary Outcome Measures
- To study the relationship between the distribution of multimers and the clinical phenotype of patients, and in particular the presence of angiodysplasias [1 year]
To study the correlation between the clinical phenotype and the assays of angiogenesis proteins
- To study the relationship between the markers of interest and the clinical phenotype of patients, and in particular the presence of angiodysplasias [1 year]
To study the correlation between the clinical phenotype and the distribution of multimers
Eligibility Criteria
Criteria
Inclusion Criteria:
For patients:
-
Patient with von Willebrand disease proven by genetic analysis of the VWF gene.
-
Lack of treatment that could interfere with angiogenesis.
-
Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
For the control:
-
Patient with a normal coagulation report
-
Absence of abnormal hemorrhagic symptoms
-
Lack of notion of angiodysplasia.
-
Lack of treatment that could interfere with angiogenesis.
-
Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
Exclusion Criteria:
-
Patient under guardianship or curatorship.
-
Pregnant and lactating women.
-
Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.
-
Treatment which may interfere with angiogenesis.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU de Nantes | Nantes | France |
Sponsors and Collaborators
- Nantes University Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RC20_0531